Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Men4age study
2024-513640-29-00Phase 4Authorised
- Sponsor
- National Institute for Public Health and the Environment
- Start
- May 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4 trial of Meningococcal polysaccharide vaccine group W-135 in meningococcal disease, meningococcemia and meningococcal meningitis (3 arms), sponsored by National Institute for Public Health and the Environment. Planned start May 2024; status: authorised.
02
Drugs
Meningococcal polysaccharide vaccine group W-135
03
Conditions
meningococcal diseasemeningococcemiameningococcal meningitis
Beyond the preview
Go deeper on 2024-513640-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513640-29-00.